Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Sciences announced that the FDA has accepted its New Drug Application for lenacapavir, a twice-yearly injectable HIV prevention treatment, under priority review with a PDUFA date of June 19, 2025. The application follows Breakthrough Therapy Designation granted in October 2024.
The NDAs are supported by Phase 3 trials PURPOSE 1 and PURPOSE 2. PURPOSE 1 showed 100% risk reduction in cisgender women, with zero infections in the lenacapavir group. PURPOSE 2 demonstrated 99.9% effectiveness with a 96% risk reduction among cisgender men and gender-diverse people, with only two HIV infections reported.
Gilead has also submitted applications to the European Medicines Agency for review under accelerated assessment, including an EU-M4all application to facilitate availability in low and lower-middle-income countries.
Gilead Sciences (GILD) has announced a 2.6% increase in its quarterly cash dividend, which will take effect in the first quarter of 2025. The new dividend will be $0.79 per share of common stock, payable on March 28, 2025, to stockholders of record as of March 14, 2025.
The dividend increase demonstrates the company's commitment to returning value to shareholders, though future dividends will remain subject to Board approval. Gilead Sciences continues its focus on developing innovative medicines for HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations spanning more than 35 countries worldwide.
Gilead Sciences (GILD) reported strong financial results for Q4 and full year 2024. Total revenue increased 6% to $28.8 billion for the full year, driven by higher sales in HIV, Oncology, and Liver Disease. Product sales excluding Veklury grew 8% to $26.8 billion.
Key highlights include Biktarvy sales increasing 13% to $13.4 billion, HIV product sales rising 8% to $19.6 billion, and Oncology sales growing 12% to $3.3 billion for full year 2024. The company's cash position strengthened to $10.0 billion by year-end.
For 2025 guidance, Gilead expects product sales between $28.2-28.6 billion, with non-Veklury sales of $26.8-27.2 billion. The company projects diluted EPS of $5.95-6.35 and non-GAAP diluted EPS of $7.70-8.10.
Cognizant (NASDAQ: CTSH) has expanded its partnership with Gilead Sciences (NASDAQ: GILD) to enhance value creation through advanced technology applications. The expanded agreement focuses on delivering cost leadership and productivity improvements through AI-driven solutions.
The collaboration will leverage Cognizant's Neuro AI generative AI platform to accelerate value creation, enhance IT and business processes, and improve operational efficiencies across customer service, employee interactions, and business value management. The partnership aims to generate significant cost savings that can be reinvested into Gilead's core life sciences business.
Building on their decade-long relationship supporting Gilead's global IT infrastructure, Cognizant will implement custom-built Gen AI solutions to transform user experience and boost operational efficiency. This expansion enables Gilead to focus on its mission of developing treatments for cancer, HIV, and other diseases while optimizing its technological capabilities.
Gilead Sciences (GILD) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025, after market close. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, including 2025 guidance.
The live webcast will be accessible through the Investors section of Gilead's website and will remain archived there for one year. The biopharmaceutical company, headquartered in Foster City, California, operates in more than 35 countries and focuses on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences (NASDAQ: GILD) and LEO Pharma announced a strategic partnership focused on developing LEO Pharma's preclinical oral STAT6 programs for inflammatory diseases. The partnership includes small molecule inhibitors and targeted protein degraders targeting STAT6, a transcription factor important for IL-4 and IL-13 cytokine signaling.
Under the agreement, Gilead will acquire global rights to develop and commercialize the oral STAT6 program, while LEO Pharma retains global rights for topical formulations in dermatology. LEO Pharma has the option to co-commercialize oral programs for dermatology outside the U.S.
The deal includes an upfront payment of $250 million to LEO Pharma, with potential total payments reaching $1.7 billion plus tiered royalties ranging from high single-digit to mid-teens on oral STAT6 product sales. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.15-$0.17.
Gilead Sciences (NASDAQ: GILD) has announced its participation in the upcoming J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will begin at 11:15 a.m. Pacific Time and will be accessible via live webcast on investors.gilead.com, with replay available for at least 30 days.
Gilead Sciences is a biopharmaceutical company with over three decades of breakthrough medical achievements. The company focuses on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Operating in more than 35 countries worldwide, Gilead is headquartered in Foster City, California.
Gilead Sciences (Nasdaq: GILD) announced that the U.S. FDA has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy. This designation is based on positive results from the Phase 2 TROPiCS-03 study, which showed promising antitumor activity and a consistent safety profile. Gilead plans to initiate a Phase 3 clinical trial in this patient population. Lung cancer is the second most diagnosed cancer in the U.S., with SCLC accounting for about 15% of cases. Approximately 70% of SCLC diagnoses are at the extensive stage, where current treatment options are and prognosis is poor. Trodelvy, a Trop-2-directed antibody-drug conjugate, is already approved for certain types of metastatic breast cancer and is being explored for multiple other cancers.
Gilead Sciences (NASDAQ: GILD) and Terray Therapeutics have announced a strategic collaboration for discovering and developing novel small molecule therapies. Terray will utilize its tNova platform, which combines high-throughput chemical experimentation and AI-driven drug discovery, to work on targets selected by Gilead.
Under the agreement, Gilead receives exclusive options to license compounds and will handle further development and commercialization. Terray will receive an upfront payment plus potential milestone payments and tiered royalties on net sales. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2024 EPS by approximately $0.01.
Gilead Sciences (GILD) received a positive CHMP opinion recommending seladelpar for treating primary biliary cholangitis (PBC) in the EU. The recommendation is based on the RESPONSE study, where 62% of participants achieved composite biochemical response at 12 months versus 20% for placebo. Notably, 25% of participants showed ALP normalization, and significant pruritus reduction was observed.
The treatment demonstrated effectiveness both in combination with ursodeoxycholic acid (UDCA) and as monotherapy for those unable to tolerate UDCA. The final European Commission decision is expected in Q1 2025. This follows the FDA's accelerated approval in August 2024. PBC affects approximately 15 per 100,000 people in Europe, primarily women.